Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx undertakes Phase II clinical trial of CCX140

Harbor BioSciences receives approval for stock listing transfer to The Nasdaq Capital Market

Harbor BioSciences receives approval for stock listing transfer to The Nasdaq Capital Market

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

ONGLYZA-metformin combination: FDA accepts NDA for review

ONGLYZA-metformin combination: FDA accepts NDA for review

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

MannKind receives FDA Complete Response letter for AFREZZA NDA

MannKind receives FDA Complete Response letter for AFREZZA NDA

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

NDA for BYDUREON: FDA issues complete response letter

NDA for BYDUREON: FDA issues complete response letter

Renowned diabetologists and healthcare professionals attend International Abu Dhabi Diabetes Congress

Renowned diabetologists and healthcare professionals attend International Abu Dhabi Diabetes Congress

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Obesity - Body's effort to protect organs from lipids' toxic effects

Obesity - Body's effort to protect organs from lipids' toxic effects

Proper treatment can help control psoriasis in most cases

Proper treatment can help control psoriasis in most cases

Novo Nordisk awarded contract by VA as primary source provider of insulin

Novo Nordisk awarded contract by VA as primary source provider of insulin

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Evolving sex disparity in midlife stroke prevalence: Further study needed

Evolving sex disparity in midlife stroke prevalence: Further study needed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.